Facility Design Webinars

  1. A Case Study In 3D Printing: Shake Flask Jackets 7/29/2026

    While experimenting with a breathable shake flask for cell culture, Vikash Kumar, a process scientist now working at Merck, needed a way to control the oxygen and carbon dioxide permeating the flask wall.

  2. Design And Material Selection When 3D Printing Parts 7/29/2026

    Process scientist Vikash Kumar needed an airtight filament when 3D printing a jacket to control oxygen and carbon dioxide around his breathable shake flask wall.

  3. Creating Technical Debt When Experimenting With 3D Printed Parts 7/29/2026

    Companies need mature validation paradigms to recognize if and when it's time to transition from a prototype 3D printed part to a sustainable version, likely through a vendor-validated part.

  4. Cooperating With Suppliers To Produce 3D-Printed Prototypes 7/29/2026

    Single-use components made with injection molding will almost always outperform compared to those made on a 3D printer.

  5. E&L Testing And 3D Printed Single-Use Parts 7/29/2026

    Bioprocess scientists may not be experts in polymer chemistry. That means getting support from resin and equipment manufacturers when conducting extractables and leachables testing.

  6. 3D Printing In Process Development And A False Sense Of Qualification 7/29/2026

    3D printing, or additive manufacturing, in early phase process development can be both a gift and an invitation for trouble. That's according to our panelists, industry leader Robert Dream and The BioProcess Institute's James Dean Vogel, during Bioprocess Online Live "The Risk And Reality Of 3D Printed Parts In Single-Use Workflows." Restricting custom design to non-product-contact parts is one way to limit the qualification burden. Due diligence is always on the operator.

  7. AST's Latest Generation GENiSYS® R: Available With Accelerated Delivery 7/28/2026

    Automated robotic fill-finish and integrated isolator technologies streamline multi-format parenteral manufacturing while ensuring regulatory compliance and maximum yield.

  8. Identifying Worst-Case Locations Assessing Homogeneity Using BIs And EIs 7/27/2026

    Combine quantitative enzyme indicators, computational fluid dynamics, and traditional biological indicators to improve VPHP isolator validation and process confidence.

  9. Enhancing Biological Indicators With Enzyme Indicators: A Complementary Approach 7/27/2026

    Quantitative enzyme indicators complement biological indicators to deliver rapid, site-specific lethality data for VPHP decontamination validation.

  10. Future-Focused Customer-Centric Bioprocessing Solutions With Eppendorf 7/24/2026

    De-risk bioprocess scale-up with application-focused workflow validation. Discover strategies for transitioning therapies from R&D to clinical production.